Document is current
Any future updates will be listed below
-
Authors
Schneider, Logan D. https://orcid.org/0000-0001-8729-5224
Ruoff, Chad M. https://orcid.org/0000-0002-1599-0858
Plante, David T. https://orcid.org/0000-0003-2619-5654
Nichols, Deborah A. https://orcid.org/0009-0005-0886-1707
Steininger, Teresa L. https://orcid.org/0009-0005-9564-0901
Fuller, Douglas S. https://orcid.org/0000-0002-2448-5896
Kirby, M. Todd
Akerman, Sarah https://orcid.org/0000-0003-0866-5245
Alexander, Jessica K.
Whalen, Marisa
Cairns, Alyssa https://orcid.org/0000-0001-6441-7751
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05875974 at ClinicalTrials.govDocuments that mention this clinical trial
Effectiveness and Safety of Low-Sodium Oxybate in Participants with Narcolepsy: Primary Results from the DUET Study
https://doi.org/10.1007/s40120-026-00921-3
Effectiveness and Safety of Low-Sodium Oxybate in Participants with Idiopathic Hypersomnia: Primary Results from the DUET Study
https://doi.org/10.1007/s40263-025-01262-9
-
Funding
Funding for this research was provided by:
Jazz Pharmaceuticals
- License Information
-
More Information
Article History
Received: 1 December 2025
Accepted: 10 March 2026
First Online: 30 April 2026
Declarations
Conflict of Interest: Logan D. Schneider has received personal compensation for serving on advisory boards and speakers bureaus for Avadel, Eisai, and Jazz Pharmaceuticals. Chad M. Ruoff has served as an advisory board member for Jazz Pharmaceuticals, Eisai, Alkermes, and Takeda and has received grant funding from Jazz Pharmaceuticals. David T. Plante is a consultant and advisory board member for Jazz Pharmaceuticals. He has also served as a consultant/advisory board member for Alkermes, Harmony Biosciences, Takeda, and Centessa, advisory board member for Apnimed, and a consultant for Aditum Bio, LLC, and Teva Pharmaceuticals (Australia). Deborah A. Nichols, Douglas S. Fuller, M. Todd Kirby, Jessica K. Alexander, Marisa Whalen, and Alyssa Cairns are full-time employees of Jazz Pharmaceuticals who, in the course of this employment, have received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals, plc. Sarah Akerman is a former full-time employee of Jazz Pharmaceuticals who, in the course of this employment, has received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals, plc. Teresa L. Steininger is a former full-time employee and current contract worker for Jazz Pharmaceuticals who has received shares of Jazz Pharmaceuticals, plc.
Ethical Approval: The study ( identifier NCT05875974) was approved by institutional review boards or ethics committees at all sites (protocol approval number Pro00071404; amendment approval numbers MOD01782418, MOD01918961, MOD02130103) and was performed in accordance with the International Conference on Harmonisation Guideline for Good Clinical Practice and the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study.
